Hancock Jaffe to rename enVVeno Medical, focus on venous disease; VenoValve trial to start

enVVeno Medical Corp

Name change to enVVeno Medical Corporation, tickers NVNO/NVNW effective Oct 1, 2021.
VenoValve SAVVE pivotal trial ready to enroll 75 patients at up to 20 U.S. centers.
Development of second venous disease product 'enVVe' initiated; expected unveil mid-2022.
CoreoGraft cardiac bypass program discontinued to focus on venous disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.